New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies are pursuing other approaches that could be even more effective or ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...